Welcome!

News Feed Item

CORRECTING and REPLACING MolecularHealth Guides Better Cancer Treatments with Two New Diagnostic Tests

Please replace the release with the following corrected version due to multiple revisions.

The corrected release reads:

MOLECULARHEALTH GUIDES BETTER CANCER TREATMENTS WITH TWO NEW DIAGNOSTIC TESTS

TreatmentMAP platform combines precision medicine with advanced data analytics to guide patients and physicians to the safest, most effective cancer treatment options

Backed by more than eight years of research and development, MolecularHealth announced today the official launch of TreatmentMAP™, its cancer treatment decision support offering. Based on a proprietary analytics engine, TreatmentMAP leverages the results of next generation sequencing (NGS) genetic tests to identify the optimal, safest treatment options for each individual patient. For the first time, cancer patients and their medical teams will have access to actionable information to guide the selection of targeted cancer treatments, presented in a clear and understandable way. TreatmentMAP became commercially available in Europe and the U.S. in April.

The company has two available versions of its offering:

  • TreatmentMAP Targeted Panel is the largest gene panel commercially available today, with over 500 genes that cover several thousand variants and have been determined to have the most clinical impact in cancer, and are therefore most likely to make a difference in treatment outcome.
  • TreatmentMAP Whole Exome, the first commercially available whole exome analysis for cancer, taking a comprehensive look at a patient’s genetic profile by examining the genes of both the tumor and germline.

Both testing options incorporate MolecularHealth’s SafetyMAP™, a proprietary identification of drug target safety or resistance effects, using the FDA’s Adverse Event Reporting Systems (AERS) as an input for analysis. Through MolecularHealth’s five-year research collaboration agreement with the FDA, MolecularHealth incorporates key data from AERS into SafetyMAP, providing the first drug safety analysis that combines adverse event information with molecular knowledge about drug activity within a patient. This ensures that treatment options will not only be effective, but won’t have unintended negative consequences for patients.

“I believe that the future of medicine lies in our ability to interpret seemingly disparate information,” said Lloyd Everson, M.D., co-CEO of MolecularHealth. “With the technology now at our disposal, there are mountains of data constantly being churned out of labs and clinical trials – but until recently, it was an unwieldy task to do anything productive with that information. TreatmentMAP allows us to pull in all of that data and make it truly usable.”

TreatmentMAP tests can be ordered in the United States and in Europe. In the U.S., a patient’s oncologist or pathologist sends a tumor sample to MolecularHealth’s CLIA-certified NGS lab in The Woodlands, Texas. Once the sample is sequenced, data on the tumor’s DNA, along with additional medical information on the patient, is fed into the company’s automated analytics platform. This platform cross-references patient-specific data with the latest peer-reviewed evidence, clinical trials, and other sources. A simple-to-understand report is delivered to the patient’s medical team, highlighting the treatment options that are most likely to be both effective and safe.

“We are still trying to understand cancer, and as an oncologist I have observed that the most effective cancer therapies are those that precisely target the unique biology of an individual patient's tumor,” said Joyce O’Shaughnessy, M.D., co-chair of breast cancer research at US Oncology and Baylor-Sammons Cancer Center. “TreatmentMAP offers new insights into the molecular drivers of a tumor, leading to expanded therapeutic options and greater chance for therapy response.”

“As a pathologist, I’m happy to have a company joining the molecular diagnostic space that’s more pathologist-friendly than some of the competition in this field,” said Thomas Wheeler, M.D., chairman of the Department of Pathology & Immunology at Baylor College of Medicine. “The market can only benefit from having more options to meet the needs of individual patients, and from what I’ve seen, MolecularHealth’s reports are not only more robust, but focus on the elements that are most important when determining a treatment path for a patient.”

Drs. O’Shaughnessy and Wheeler are members of the MolecularHealth advisory board.

For more information on TreatmentMAP and how to order a test, please visit MolecularHealth’s website.

ABOUT MOLECULARHEALTH

MolecularHealth is a leading biomedical company transforming molecular data into actionable clinical information for the most efficient and safest cancer treatment options for each individual cancer patient. By using advanced proprietary tumor analysis and interpretation to match patient-specific genetic and molecular test findings to the current state of the world’s biomedical knowledge about cancer, MolecularHealth provides doctors and patients with faster, more accurate insights into the role genes play in the progression and treatment of an individual’s cancer. Eight years in development by a multidisciplinary team of doctors, scientists and IT experts, MolecularHealth works in partnership with some of the world’s leading healthcare and information technology companies, including the U.S. Food and Drug Administration (FDA), University of Texas MD Anderson Cancer Center, and SAP AG. The company is headquartered in Heidelberg, Germany. U.S. headquarters, including a CLIA-certified NGS lab, are located in The Woodlands, Texas. The company also has offices in Boston, Mass.

Website: www.molecularhealth.com
Twitter: www.twitter.com/molecularhealth
LinkedIn: www.linkedin.com/company/molecularhealth
YouTube: www.youtube.com/user/MolecularHealthInc

More Stories By Business Wire

Copyright © 2009 Business Wire. All rights reserved. Republication or redistribution of Business Wire content is expressly prohibited without the prior written consent of Business Wire. Business Wire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
DX World EXPO, LLC, a Lighthouse Point, Florida-based startup trade show producer and the creator of "DXWorldEXPO® - Digital Transformation Conference & Expo" has announced its executive management team. The team is headed by Levent Selamoglu, who has been named CEO. "Now is the time for a truly global DX event, to bring together the leading minds from the technology world in a conversation about Digital Transformation," he said in making the announcement.
"Space Monkey by Vivent Smart Home is a product that is a distributed cloud-based edge storage network. Vivent Smart Home, our parent company, is a smart home provider that places a lot of hard drives across homes in North America," explained JT Olds, Director of Engineering, and Brandon Crowfeather, Product Manager, at Vivint Smart Home, in this SYS-CON.tv interview at @ThingsExpo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
SYS-CON Events announced today that Conference Guru has been named “Media Sponsor” of the 22nd International Cloud Expo, which will take place on June 5-7, 2018, at the Javits Center in New York, NY. A valuable conference experience generates new contacts, sales leads, potential strategic partners and potential investors; helps gather competitive intelligence and even provides inspiration for new products and services. Conference Guru works with conference organizers to pass great deals to gre...
DevOps is under attack because developers don’t want to mess with infrastructure. They will happily own their code into production, but want to use platforms instead of raw automation. That’s changing the landscape that we understand as DevOps with both architecture concepts (CloudNative) and process redefinition (SRE). Rob Hirschfeld’s recent work in Kubernetes operations has led to the conclusion that containers and related platforms have changed the way we should be thinking about DevOps and...
The Internet of Things will challenge the status quo of how IT and development organizations operate. Or will it? Certainly the fog layer of IoT requires special insights about data ontology, security and transactional integrity. But the developmental challenges are the same: People, Process and Platform. In his session at @ThingsExpo, Craig Sproule, CEO of Metavine, demonstrated how to move beyond today's coding paradigm and shared the must-have mindsets for removing complexity from the develop...
In his Opening Keynote at 21st Cloud Expo, John Considine, General Manager of IBM Cloud Infrastructure, led attendees through the exciting evolution of the cloud. He looked at this major disruption from the perspective of technology, business models, and what this means for enterprises of all sizes. John Considine is General Manager of Cloud Infrastructure Services at IBM. In that role he is responsible for leading IBM’s public cloud infrastructure including strategy, development, and offering m...
The next XaaS is CICDaaS. Why? Because CICD saves developers a huge amount of time. CD is an especially great option for projects that require multiple and frequent contributions to be integrated. But… securing CICD best practices is an emerging, essential, yet little understood practice for DevOps teams and their Cloud Service Providers. The only way to get CICD to work in a highly secure environment takes collaboration, patience and persistence. Building CICD in the cloud requires rigorous ar...
Companies are harnessing data in ways we once associated with science fiction. Analysts have access to a plethora of visualization and reporting tools, but considering the vast amount of data businesses collect and limitations of CPUs, end users are forced to design their structures and systems with limitations. Until now. As the cloud toolkit to analyze data has evolved, GPUs have stepped in to massively parallel SQL, visualization and machine learning.
"Evatronix provides design services to companies that need to integrate the IoT technology in their products but they don't necessarily have the expertise, knowledge and design team to do so," explained Adam Morawiec, VP of Business Development at Evatronix, in this SYS-CON.tv interview at @ThingsExpo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
To get the most out of their data, successful companies are not focusing on queries and data lakes, they are actively integrating analytics into their operations with a data-first application development approach. Real-time adjustments to improve revenues, reduce costs, or mitigate risk rely on applications that minimize latency on a variety of data sources. In his session at @BigDataExpo, Jack Norris, Senior Vice President, Data and Applications at MapR Technologies, reviewed best practices to ...
Widespread fragmentation is stalling the growth of the IIoT and making it difficult for partners to work together. The number of software platforms, apps, hardware and connectivity standards is creating paralysis among businesses that are afraid of being locked into a solution. EdgeX Foundry is unifying the community around a common IoT edge framework and an ecosystem of interoperable components.
"ZeroStack is a startup in Silicon Valley. We're solving a very interesting problem around bringing public cloud convenience with private cloud control for enterprises and mid-size companies," explained Kamesh Pemmaraju, VP of Product Management at ZeroStack, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
Large industrial manufacturing organizations are adopting the agile principles of cloud software companies. The industrial manufacturing development process has not scaled over time. Now that design CAD teams are geographically distributed, centralizing their work is key. With large multi-gigabyte projects, outdated tools have stifled industrial team agility, time-to-market milestones, and impacted P&L stakeholders.
"Akvelon is a software development company and we also provide consultancy services to folks who are looking to scale or accelerate their engineering roadmaps," explained Jeremiah Mothersell, Marketing Manager at Akvelon, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
Enterprises are adopting Kubernetes to accelerate the development and the delivery of cloud-native applications. However, sharing a Kubernetes cluster between members of the same team can be challenging. And, sharing clusters across multiple teams is even harder. Kubernetes offers several constructs to help implement segmentation and isolation. However, these primitives can be complex to understand and apply. As a result, it’s becoming common for enterprises to end up with several clusters. Thi...